Eledon Pharmaceuticals
ELDN
16 hedge funds and large institutions have $13.6M invested in Eledon Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
1% more capital inflows, than outflows
Capital inflows: $246K | Capital outflows: $244K
0% more funds holding
Funds holding: 16 → 16 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.15% less ownership
Funds ownership: 35.97% → 35.82% (-0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$146K |
| 2 |
Morgan Stanley
New York
|
+$44.1K |
| 3 |
Seelaus Asset Management
Chatham,
New Jersey
|
+$36.9K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
+$15.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$120K |
| 2 |
Renaissance Technologies
New York
|
-$118K |
| 3 |
BlackRock
New York
|
-$3.45K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 5 |
Meeder Asset Management
Dublin,
Ohio
|
-$929 |
ELDN Hedge Fund Activity: Q1 2019 in Review
16 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2019, worth a combined $13.6M — up 150% from $5.43M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ELDN positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was B. Riley Wealth Advisors, adding an estimated $146K. The largest seller was Deutsche Bank, cutting an estimated $120K.
- 16 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $13.6M of Eledon Pharmaceuticals stock for Q1 2019, up 150% quarter-over-quarter.
- 3 funds opened new Eledon Pharmaceuticals positions in Q1 2019 and 2 closed out, a net change of +1 holder.
- The largest Eledon Pharmaceuticals buyer in Q1 2019 was B. Riley Wealth Advisors, an estimated $146K added.
- The largest Eledon Pharmaceuticals seller in Q1 2019 was Deutsche Bank, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2019.